SNTI Senti Biosciences Holdings, Inc.
Mergers ·
Senti adjourned its October 8, 2026 annual meeting without conducting any business to seek more votes for a merger proposal. The company reported $6.5 million of cash and cash equivalents at June 30, 2026, after using $43.4 million in operations in 2025.
The notes were issued under an April 27, 2026 purchase agreement, as amended on September 1, 2026. A separate $2.5 million equity commitment was signed the same day.
Nasdaq flagged Senti's sub-$1 share price and a stockholders' deficit below the $2.5 million minimum. The bid-price clock runs to Feb. 23, 2027; the equity plan is due Oct. 11.
The notes were issued under an April 27, 2026 purchase agreement. The filing also ties the company to a potential merger with a contingent value right that could pay up to $60.0 million in cash.
Senti Biosciences agreed on July 14, 2026 to move most of its business, including lead candidate SENTI-202, to an affiliate of its largest stockholder. Holders would receive contingent value rights worth up to $60 million that pay only if milestones are met, while the company used $43.4 million in operations in 2025.
Celadon Partners SPV 24 bought the notes, and Acquiom Agency Services LLC was named collateral agent.
An affiliate of Celadon Partners SPV 24 may buy notes in two tranches. The first tranche is $10 million and is expected to close in May.
Senti Biosciences agreed to sell up to $40.0 million of secured convertible notes to an affiliate of its largest stockholder. If the notes are not converted, the company must pay 200% of principal in cash at maturity, and the second tranche depends on a related deal that could pay up to $60.0 million.
Leerink Partners will act as sales agent for a 3.0% commission. The company's public float was approximately $57.81 million.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | |
| Research and development | $37.6 million | $34.4 million |
| Net income (loss) | -$61.4 million | -$52.8 million |
| Cash from operations | -$43.4 million | -$41.4 million |
| Cash and equivalents | $16.4 million | $48.3 million |
Our latest story on this, dated Mar 24, 2025: "Senti Biosciences files $300,000,000 shelf and sets up $17,500,000 at-the-market program". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 3, 2026: "Senti Biosciences unit sells $2.0 million in convertible notes to NSG". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 27, 2026: "Senti Biosciences gets two Nasdaq notices, on bid price and a $3.4M equity deficit". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 13, 2026: "Senti Biosciences adjourns annual meeting to seek more votes for merger proposal". The story links the filing or release it is based on. Read the story.
Senti Biosciences Holdings, Inc. trades under the ticker SNTI on NASDAQ.
Senti Biosciences Holdings, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Senti Biosciences Holdings, Inc. is 1854270. Its filings are on SEC EDGAR.
31,144,754 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Senti Biosciences Holdings, Inc. under United States.
Our directory classifies Senti Biosciences Holdings, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Senti Biosciences Holdings, Inc. is US8169441024.
aibio.space lists Senti Biosciences Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Senti Biosciences Holdings, Inc. reported a net loss of $61.4 million for the fiscal year ended Dec 31, 2025, and used $43.4 million of cash in operations, per its annual report to the SEC.
$37.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,3.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.02,5.01,7.01,8.01,9.01). Source
Filed to end its SEC reporting. SEC Form 15-12G. Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 2.03,3.02,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,3.03,5.02,5.03,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio